Table 7.

Simulated preferences for treatment under various potential treatment scenarios.

Attributes and reference level	The change in the probability	95% Confidence intervals
Cost: 5 ten thousand (ref: 1 ten thousand)	−59.91%***	(−64.26%; −55.57%)
Cost: 2.5 ten thousand (ref: 1 ten thousand)	−25.37%***	(−27.75%; −23.00%)
Progression-free survival: 11 months (ref: 5 months)	33.06%***	(26.53%; 39.60%)
Progression-free survival: 8 months (ref: 5 months)	19.29%***	(13.72%; 24.86%)
Disease control rate: 90% (ref: 60%)	33.17%***	(26.69%; 39.66%)
Disease control rate: 75% (ref: 60%)	16.88%***	(10.52%; 23.24%)
Rash: none (ref: moderate)	5.36%	(−0.93%; 11.65%)
Rash: mild (ref: moderate)	3.42%	(−3.22%; 10.06%)
Nausea and vomiting: mild (ref: severe)	18.38%***	(12.47%; 24.30%)
Nausea and vomiting: moderate (ref: severe)	6.95%*	(1.06%; 12.84%)
Weakness and fatigue: mild (ref: severe)	22.44%***	(16.34%; 28.55%)
Weakness and fatigue: moderate (ref: severe)	8.75%**	(2.66%; 14.85%)
Mode of administration: Infusion (ref: Oral)	1.91%	(−2.75%; 6.57%)

^*Significant at 5% level,

^**significant at 10% level,

^***significant at 1% level.